AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26334339 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 89
Study 23757615 — intervention group
Group type: EXPERIMENTAL
Intervention: SITA/MET FDC 50/500 mg b.i.d. (uptitrated to 50/1,000 mg b.i.d.)
Number of subjects: 1250
Study 23757615 — intervention group
Group type: COMPARATOR
Intervention: MET 500 mg b.i.d. (uptitrated to 1,000 mg b.i.d.)
Number of subjects: 1250
Study 21559034 — intervention group
Group type: EXPERIMENTAL
Intervention: WeighWell intervention (motivational interviewing techniques, energy deficit diet, increased physical activity, 12-week duration, 3 face-to-face consultations, 3 structured telephone calls)
Number of subjects: 52
Study 21559034 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific intervention details provided)
Number of subjects: 52
Study 19628939 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (weekly sessions of individual, receptive music therapy using the validated 'U' technique)
Number of subjects: 30
Study 19628939 — intervention group
Group type: COMPARATOR
Intervention: Reading sessions (control group)
Number of subjects: 30
Study 17259554 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy combined with growth factor pathway inhibitors
Number of subjects: 0
Study 17259554 — intervention group
Group type: COMPARATOR
Intervention: Selective estrogen receptor modulator tamoxifen
Number of subjects: 0
Study 17259554 — intervention group
Group type: COMPARATOR
Intervention: Aromatase inhibitors
Number of subjects: 0
Study 17259554 — intervention group
Group type: COMPARATOR
Intervention: Pure ER antagonists
Number of subjects: 0
Study 15235928 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizoribine (MZ) onlay therapy
Number of subjects: 52
Study 15235928 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 52
Study 11763976 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 400 microg misoprostol, 8 h before aspiration
Number of subjects: 900
Study 11763976 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal self‐administration of 400 microg misoprostol, 4 h before aspiration
Number of subjects: 900
Study 9409230 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (5 g eicosapentaenoic acid and docosahexaenoic acid per day)
Number of subjects: 41
Study 9409230 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (75 mg vitamin E, 150 mg vitamin C, 15 mg beta-carotene, and 30 mg coenzyme Q10 per day)
Number of subjects: 41
Study 9409230 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids and antioxidants
Number of subjects: 41
Study 9409230 — intervention group
Group type: COMPARATOR
Intervention: Control oils
Number of subjects: 41
Study 8513310 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (A) 5,10mg
Number of subjects: 50
Study 8513310 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (N) 10,20mg
Number of subjects: 50
Study 8513310 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 50
Study 3321849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (4 mg, i.v. injection)
Number of subjects: 53
Study 3321849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 30378090 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 20
Study 30378090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27357095 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc carnosine (ZnC)
Number of subjects: 8
Study 27357095 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Number of subjects: 8
Study 27357095 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc carnosine (ZnC) plus bovine colostrum
Number of subjects: 8
Study 27357095 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro studies with ZnC or colostrum
Number of subjects: 8
Study 27357095 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (ZnC + colostrum)
Number of subjects: 8
Study 27357095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 24778433 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Number of subjects: 0
Study 24778433 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy
Number of subjects: 0
Study 23311173 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicines (Xiaozhi decoction), twice daily for 6 weeks
Number of subjects: 72
Study 23311173 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine (0.5 g azithromycin for 3 days, 6 courses of treatment, each course lasting 4 days)
Number of subjects: 72
Study 23311173 — intervention group
Group type: COMPARATOR
Intervention: Control group (32 infertile women with negative mycoplasma culture)
Number of subjects: 72
Study 20624316 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute daily physical education sessions based on early psychomotor education
Number of subjects: 41
Study 20624316 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 41
Study 20624316 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute daily physical education sessions
Number of subjects: 41
Study 18179460 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible-dose sildenafil for ED treatment
Number of subjects: 213
Study 18179460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 16565867 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine support (Health Buddy computer providing daily Internet-based support)
Number of subjects: 0
Study 16565867 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 0
Study 12037369 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental dentifrice formulation containing stannous fluoride (SnF(2))
Number of subjects: 0
Study 12037369 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental dentifrice formulation containing sodium fluoride (NaF)
Number of subjects: 0
Study 12037369 — intervention group
Group type: COMPARATOR
Intervention: SnF(2) positive control
Number of subjects: 0
Study 12037369 — intervention group
Group type: COMPARATOR
Intervention: NaF positive control
Number of subjects: 0
Study 12037369 — intervention group
Group type: COMPARATOR
Intervention: No-fluoride placebo negative control
Number of subjects: 0
Study 10447990 — intervention group
Group type: EXPERIMENTAL
Intervention: Right mouth asymmetry (RMA) during speech production
Number of subjects: 20
Study 8573730 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine (20 mg/day)
Number of subjects: 7
Study 2128700 — intervention group
Group type: EXPERIMENTAL
Intervention: Requirement-adapted peripheral-venous parenteral nutrition with maltose and fat emulsion (650 mosm/l; 2,000 kcal)
Number of subjects: 0
Study 2128700 — intervention group
Group type: COMPARATOR
Intervention: Common requirement-adapted parenteral nutrition regimen via central-venous catheter (2,000 mosm/l; 2,000 kcal)
Number of subjects: 0
Study 911576 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 0
Study 911576 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine
Number of subjects: 0
Study 31564377 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma α‐linolenic acid levels
Number of subjects: 426824
Study 31564377 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma linoleic acid levels
Number of subjects: 426824
Study 31564377 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma palmitoleic acid levels
Number of subjects: 426824
Study 31564377 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma oleic acid levels
Number of subjects: 426824
Study 31564377 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma arachidonic acid levels
Number of subjects: 426824
Study 31564377 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma eicosapentaenoic acid levels
Number of subjects: 426824
Study 31564377 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma docosapentanenoic acid levels
Number of subjects: 426824
Study 31564377 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma stearic acid levels
Number of subjects: 426824
Study 30234850 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)-OSU6162
Number of subjects: 52
Study 30234850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 29173735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 20 to 80 mg/day
Number of subjects: 347
Study 29173735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 25500487 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg canagliflozin
Number of subjects: 27
Study 25500487 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg canagliflozin
Number of subjects: 27
Study 25500487 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg canagliflozin
Number of subjects: 27
Study 25500487 — intervention group
Group type: EXPERIMENTAL
Intervention: canagliflozin (all doses)
Number of subjects: 27
Study 23816023 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) bolus abciximab
Number of subjects: 452
Study 23816023 — intervention group
Group type: COMPARATOR
Intervention: No abciximab
Number of subjects: 452
Study 23816023 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Number of subjects: 452
Study 23816023 — intervention group
Group type: COMPARATOR
Intervention: No aspiration
Number of subjects: 452
Study 21801326 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting posture
Number of subjects: 115
Study 21801326 — intervention group
Group type: COMPARATOR
Intervention: Standing posture
Number of subjects: 115
Study 19454544 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 46
Study 19454544 — intervention group
Group type: COMPARATOR
Intervention: Classic laryngeal mask airway (cLMA)
Number of subjects: 46
Study 15193684 — intervention group
Group type: EXPERIMENTAL
Intervention: Chylomicron‐like emulsion labeled with radioactive triglyceride (3H‐TG) and cholesteryl esters (14C‐CE)
Number of subjects: 63
Study 15193684 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed intravascular TG lipolysis
Number of subjects: 63
Study 11239981 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective attention procedure with odorants in mixtures of one to four components (Experiment 1)
Number of subjects: 35
Study 11239981 — intervention group
Group type: EXPERIMENTAL
Intervention: Profiling procedure with 146 descriptors for odor qualities (Experiment 2)
Number of subjects: 35
Study 11185629 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of [14C]telmisartan 40 mg
Number of subjects: 10
Study 11185629 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of [14C]telmisartan 40 mg
Number of subjects: 10
Study 11185629 — intervention group
Group type: COMPARATOR
Intervention: Both oral and intravenous administration
Number of subjects: 10
Study 8842072 — intervention group
Group type: EXPERIMENTAL
Intervention: Posturography and clinical assessment (physical examination, dizziness provocation, and psychological assessment)
Number of subjects: 149
Study 8842072 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnostic criteria based on accepted definitions
Number of subjects: 149
Study 8842072 — intervention group
Group type: EXPERIMENTAL
Intervention: Common diagnoses identified
Number of subjects: 149
Study 8842072 — intervention group
Group type: COMPARATOR
Intervention: Blood profile, electrocardiography, electronystagmography, and magnetic resonance imaging
Number of subjects: 149
Study 1537780 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride (CMI)
Number of subjects: 0
Study 1537780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6434117 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose antacid (10 ml as required)
Number of subjects: 69
Study 6434117 — intervention group
Group type: COMPARATOR
Intervention: Low dose placebo
Number of subjects: 69
Study 6434117 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose antacid (30 ml seven times daily)
Number of subjects: 69
Study 6434117 — intervention group
Group type: COMPARATOR
Intervention: High dose placebo
Number of subjects: 69
Study 29420230 — intervention group
Group type: EXPERIMENTAL
Intervention: Various recruitment strategies including providing trial information in the prehospital setting, technology for covering multiple sites, screening logs, and verbal consent.
Number of subjects: 39
Study 29420230 — intervention group
Group type: EXPERIMENTAL
Intervention: Nested RCT evaluating a recruitment intervention.
Number of subjects: 39
Study 29420230 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports of recruitment experiences from real RCTs and hypothetical RCTs.
Number of subjects: 39
Study 27085660 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy (CEA) plus Best Medical Treatment (BMT)
Number of subjects: 513
Study 27085660 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting (CAS) plus Best Medical Treatment (BMT)
Number of subjects: 513
Study 27085660 — intervention group
Group type: COMPARATOR
Intervention: Best Medical Treatment (BMT) alone
Number of subjects: 513
Study 24581465 — intervention group
Group type: EXPERIMENTAL
Intervention: Port infection group (33 patients with infection)
Number of subjects: 4404
Study 24581465 — intervention group
Group type: COMPARATOR
Intervention: Control group (66 patients with no infection)
Number of subjects: 4404
Study 24581465 — intervention group
Group type: EXPERIMENTAL
Intervention: Port infection group
Number of subjects: 4404
Study 22672186 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutures
Number of subjects: 0
Study 22672186 — intervention group
Group type: COMPARATOR
Intervention: Staples
Number of subjects: 0
Study 19889649 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent (BES) with biodegradable polymer
Number of subjects: 56
Study 19889649 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES) with durable polymer
Number of subjects: 56
Study 17966008 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (n = 136)
Number of subjects: 272
Study 17966008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 136)
Number of subjects: 272
Study 16340371 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depleting filter at 35 degrees C
Number of subjects: 80
Study 16340371 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depleting filter at 28 degrees C
Number of subjects: 80
Study 16340371 — intervention group
Group type: COMPARATOR
Intervention: Non-leukocyte-depleting filter (Control) at 35 degrees C
Number of subjects: 80
Study 16340371 — intervention group
Group type: COMPARATOR
Intervention: Non-leukocyte-depleting filter (Control) at 28 degrees C
Number of subjects: 80
Study 12410513 — intervention group
Group type: COMPARATOR
Intervention: iodixanol 320 (Visipaque)
Number of subjects: 618
Study 12410513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 618
Study 9883284 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-hour small-group informational and skill-building intervention
Number of subjects: 472
Study 9883284 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 472
Study 7612715 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal nasogastric tube feeding (30% additional caloric charge)
Number of subjects: 16
Study 7612715 — intervention group
Group type: COMPARATOR
Intervention: Oral feeding ad libitum (control group)
Number of subjects: 16
Study 2773895 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mmol acetate plus 60 mmol propionate (180 mM; hypertonic)
Number of subjects: 6
Study 2773895 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mmol sodium acetate plus 30 mmol sodium propionate (90 mM; isotonic)
Number of subjects: 6
Study 2773895 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 6
Study 30267607 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured playtime in natural environments
Number of subjects: 29
Study 30267607 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers and facilitators to play
Number of subjects: 29
Study 29741754 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (2 capsules of Lactobacillus rhamnosus GG daily for 6 months)
Number of subjects: 209
Study 29741754 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium carbonate)
Number of subjects: 209
Study 26674898 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g (2 × 500 mg) tranexamic acid tablets before surgery
Number of subjects: 50
Study 26674898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25140000 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy combined with bevacizumab
Number of subjects: 158
Study 25140000 — intervention group
Group type: EXPERIMENTAL
Intervention: High EGFL7 VA
Number of subjects: 158
Study 25140000 — intervention group
Group type: EXPERIMENTAL
Intervention: miR126 vessel area (VA)
Number of subjects: 158
Study 22363673 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT monotherapy
Number of subjects: 23
Study 19148838 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids in patients with prior myocardial infarction (MI)
Number of subjects: 20997
Study 19148838 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids in patients with angina
Number of subjects: 20997
Study 19148838 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 20997
Study 18626295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) + imipramine
Number of subjects: 0
Study 18626295 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) + placebo
Number of subjects: 0
Study 16043433 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (DSF)
Number of subjects: 100
Study 16043433 — intervention group
Group type: COMPARATOR
Intervention: Acamprosate (ACP)
Number of subjects: 100
Study 12442934 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 50
Study 12442934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10325832 — intervention group
Group type: EXPERIMENTAL
Intervention: Global haemodynamic variables
Number of subjects: 68
Study 10325832 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure on admission
Number of subjects: 68
Study 10325832 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure at 12 h
Number of subjects: 68
Study 10325832 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean pulmonary artery pressure on admission
Number of subjects: 68
Study 10325832 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean pulmonary artery pressure at 12 h
Number of subjects: 68
Study 10325832 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric pHi on admission
Number of subjects: 68
Study 10325832 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric pHi at 12 h
Number of subjects: 68
Study 10325832 — intervention group
Group type: EXPERIMENTAL
Intervention: delta PCO2 on admission
Number of subjects: 68
Study 10325832 — intervention group
Group type: EXPERIMENTAL
Intervention: delta PCO2 at 12 h
Number of subjects: 68
Study 8965037 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroid injection
Number of subjects: 0
Study 8965037 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltoid muscle injection
Number of subjects: 0
Study 8965037 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 1743321 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms GnRH pulse dose
Number of subjects: 15
Study 1743321 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms GnRH pulse dose
Number of subjects: 15
Study 1743321 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms GnRH pulse dose
Number of subjects: 15
Study 1743321 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction cycles
Number of subjects: 15
Study 1743321 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous menstrual cycles
Number of subjects: 15
Study 7039017 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (RATG)
Number of subjects: 20
Study 7039017 — intervention group
Group type: COMPARATOR
Intervention: High oral doses of prednisone
Number of subjects: 20
Study 7039017 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RATG and prednisone)
Number of subjects: 20
Study 30586746 — intervention group
Group type: EXPERIMENTAL
Intervention: ALD-401 infusion
Number of subjects: 100
Study 30586746 — intervention group
Group type: COMPARATOR
Intervention: Sham infusion
Number of subjects: 100
Study 29070115 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate combined with rituxan (targeted treatment group)
Number of subjects: 100
Study 29070115 — intervention group
Group type: COMPARATOR
Intervention: High-dose methotrexate combined with whole brain radiotherapy (traditional treatment group)
Number of subjects: 100
Study 26091461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) administered at a loading dose of 0.5 μg/kg for 10 minutes, followed by an infusion rate of 0.4 μg/kg/h from insufflation of the pneumoperitoneum to the end of surgery.
Number of subjects: 92
Study 26091461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) administered as described above.
Number of subjects: 92
Study 26091461 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 92
Study 23512419 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.04 mg/kg iv followed by 0.01 mg/kg/h infusion for 24 h
Number of subjects: 60
Study 23512419 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study 21235724 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal prolapse surgery
Number of subjects: 65
Study 21235724 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal prolapse surgery with incontinence surgery
Number of subjects: 65
Study 21235724 — intervention group
Group type: COMPARATOR
Intervention: Abdominal prolapse surgery only
Number of subjects: 65